ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.034,63
1,36%
S&P 500
5.770,20
0,55%
US Dollar vs BRL
5,7879
0,00%
Bitcoin
84.219,00
-2,25%
Brent Oil
70,235
0,00%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Amneal Pharmaceuticals Inc (AMRX)

  7. Amneal Pharmaceuticals Inc (AMRX) Notícias

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AMRX
DataHoraFonteTítuloCódigoCompanhia
07/03/202518:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
05/03/202519:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
28/02/202508:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRXAmneal Pharmaceuticals Inc
28/02/202508:00Business WireAmneal Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:AMRXAmneal Pharmaceuticals Inc
19/02/202510:00Business WireAmneal Launches Mesalamine and Receives U.S. FDA Approval for LenalidomideNASDAQ:AMRXAmneal Pharmaceuticals Inc
29/01/202510:30Business WireAmneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025NASDAQ:AMRXAmneal Pharmaceuticals Inc
23/01/202519:49Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
23/01/202510:00Business WireAmneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for RifaximinNASDAQ:AMRXAmneal Pharmaceuticals Inc
04/12/202410:00Business WireAmneal to Participate at Upcoming Investor ConferencesNASDAQ:AMRXAmneal Pharmaceuticals Inc
21/11/202418:05Business WireAmneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistNASDAQ:AMRXAmneal Pharmaceuticals Inc
14/11/202418:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
12/11/202418:25Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
08/11/202408:00Business WireAmneal Reports Third Quarter 2024 Financial ResultsNASDAQ:AMRXAmneal Pharmaceuticals Inc
31/10/202419:51Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
21/10/202409:00Business WireAmneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release TabletsNASDAQ:AMRXAmneal Pharmaceuticals Inc
08/10/202417:05Business WireAmneal to Report Third Quarter 2024 Results on November 8, 2024NASDAQ:AMRXAmneal Pharmaceuticals Inc
01/10/202407:00Business WireAmneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic DiseasesNASDAQ:AMRXAmneal Pharmaceuticals Inc
09/08/202417:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRXAmneal Pharmaceuticals Inc
13/05/202417:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
25/01/202409:30GlobeNewswire Inc.Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203NASDAQ:AMRXAmneal Pharmaceuticals Inc
05/01/202418:09Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AMRXAmneal Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AMRX

Seu Histórico Recente

ASX
TMGOD
Trigg Minerals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios